血小板与淋巴细胞比值在恶性肿瘤预后中的研究进展
摘要
关键词
全文:
PDF参考
[1]马祎菲, 梁新军, 魏少忠. 炎症与免疫指标在可切除性结直肠癌中的预后价值 [J]. 中国癌症杂志, 2021, 31(9): 845-51.
[2]PEI Q, LUO Y, CHEN Y, et al. Artificial intelligence in clinical applications for lung cancer: diagnosis, treatment and prognosis [J].
Clin Chem Lab Med, 2022, 60(12): 1974-83.
[3]FEIER C V I, MUNTEAN C, FAUR A M, et al. Exploring Inflammatory Parameters in Lung Cancer Patients: A Retrospective
Analysis [J]. J Pers Med, 2024, 14(6).
[4]CHEN N, LI W, HUANG K, et al. Increased platelet-lymphocyte ratio closely relates to inferior clinical features and worse long-term
survival in both resected and metastatic colorectal cancer: an updated systematic review and meta-analysis of 24 studies [J]. Oncotarget,
2017, 8(19): 32356-69.
[5]MISIEWICZ A, DYMICKA-PIEKARSKA V. Fashionable, but What is Their Real Clinical Usefulness? NLR, LMR, and PLR as a
Promising Indicator in Colorectal Cancer Prognosis: A Systematic Review [J]. J Inflamm Res, 2023, 16: 69-81.
[6]ZHANG C-L, JIANG X-C, LI Y, et al. Independent predictive value of blood inflammatory composite markers in ovarian cancer:
recent clinical evidence and perspective focusing on NLR and PLR [J]. Journal of Ovarian Research, 2023, 16(1).
[7]SHI L, QIN X, WANG H, et al. Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased
platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma [J]. Oncotarget, 2017, 8(12): 18792-801.
(4 摘要 Views, 5 PDF Downloads)
Refbacks
- 当前没有refback。